{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:31:18Z","timestamp":1794108678443,"version":"4.8.0"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000982","name":"ASCO Foundation","doi-asserted-by":"publisher","award":["GR0245555"],"award-info":[{"award-number":["GR0245555"]}],"id":[{"id":"10.13039\/100000982","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006293","name":"American Society of Clinical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006293","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["P30CA008748"],"award-info":[{"award-number":["P30CA008748"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["R35CA263816"],"award-info":[{"award-number":["R35CA263816"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["U24CA213274"],"award-info":[{"award-number":["U24CA213274"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.lungcan.2026.109390","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:54:20Z","timestamp":1774972460000},"page":"109390","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer"],"prefix":"10.1016","volume":"216","author":[{"given":"Alissa J.","family":"Cooper","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Arfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiktoria","family":"Bogdanska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8770-6425","authenticated-orcid":false,"given":"Jessica S.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3567-965X","authenticated-orcid":false,"given":"Phoebe","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bobby","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin F.","family":"Gainor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles M.","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B.","family":"Meador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.lungcan.2026.109390_b0005","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"10212","key":"10.1016\/j.lungcan.2026.109390_b0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lungcan.2026.109390_b0015","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2026.109390_b0020","doi-asserted-by":"crossref","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"Firth","year":"1993","journal-title":"Biometrika"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109390_b0025","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection - a review and recommendations for the practicing statistician","volume":"60","author":"Heinze","year":"2018","journal-title":"Biom. J."},{"key":"10.1016\/j.lungcan.2026.109390_b0030","unstructured":"I, K., brglm2: Bias Reduction in Generalized Linear Models. 2025. p. R package version."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109390_b0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin. Lung Cancer"},{"issue":"2","key":"10.1016\/j.lungcan.2026.109390_b0040","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cllc.2025.11.018","article-title":"Optimizing tarlatamab delivery in small cell and neuroendocrine lung cancer: real-world insights into step-up dosing and prophylactic tocilizumab use","volume":"27","author":"Joshi","year":"2025","journal-title":"Clin. Lung Cancer"},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109390_b0045","doi-asserted-by":"crossref","first-page":"8088","DOI":"10.1200\/JCO.2025.43.16_suppl.8088","article-title":"Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer","volume":"43","author":"Parma","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109390_b0050","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e20120","article-title":"Real world outcomes of patients treated with tarlatamab in extensive stage small cell lung cancer","volume":"43","author":"Karam","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2026.109390_b0055","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/1753425917707026","article-title":"Sex differences in the pro-inflammatory cytokine response to endotoxin unfold in vivo but not ex vivo in healthy humans","volume":"23","author":"Wegner","year":"2017","journal-title":"Innate Immun."},{"issue":"16_suppl","key":"10.1016\/j.lungcan.2026.109390_b0060","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2023.41.16_suppl.2646","article-title":"Sex differences in burden of adverse events in patients receiving immunotherapy","volume":"41","author":"Miceli","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lungcan.2026.109390_b0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.jaad.2021.06.885","article-title":"Female sex is associated with higher rates of dermatologic adverse events among patients with melanoma receiving immune checkpoint inhibitor therapy: a retrospective cohort study","volume":"87","author":"Bui","year":"2022","journal-title":"J. Am. Acad. Dermatol."},{"issue":"7","key":"10.1016\/j.lungcan.2026.109390_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17071054","article-title":"Sex-related differences in immunotherapy toxicities: insights into dimorphic responses","volume":"17","author":"Canzian","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.lungcan.2026.109390_b0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/cmi.2016.3","article-title":"Liver immunology and its role in inflammation and homeostasis","volume":"13","author":"Robinson","year":"2016","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2026.109390_b0080","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br. J. Haematol."},{"issue":"21","key":"10.1016\/j.lungcan.2026.109390_b0085","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"224","key":"10.1016\/j.lungcan.2026.109390_b0090","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.lungcan.2026.109390_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.611366","article-title":"Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500226004514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T16:21:34Z","timestamp":1782663694000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500226004514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":19,"alternative-id":["S0169500226004514"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109390","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world multi-institution analysis of tarlatamab in patients with small cell lung cancer","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2026.109390","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"109390"}}